Research from PharmAlliance collaborators (published March, 2020) revealed changes in intestinal permeability and oral absorption for some medications in mouse models of Alzheimer’s Disease. The drugs that showed a decrease in oral absorption, digoxin and valsartan, are commonly prescribed medications for cardiac conditions. Often times, patients with Alzheimer’s Disease are also being treated for cardiac conditions with these medications. This research was conducted in mouse models; however, if the findings are similar in humans, this research could change the way some medications are dosed in patients with Alzheimer’s Disease.

See more on this research from the American Chemistry Society News Service Weekly PressPac.

Congratulations to authors Liang Jin*, Natalie Lan Linh Tran*, Leon N. Polychronopoulos*, Aparna Warrier*, Kim L. R. Brouwer**, and Joseph A. Nicolazzo*

*Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
**Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Leave a Reply

Your email address will not be published.